Anebulo Pharmaceuticals, Inc. · OTC:ANEB
Anebulo Pharmaceuticals — IPO Roadshow (April 2021)
26 slides from Anebulo Pharmaceuticals's IPO roadshow presentation, Apr 26, 2021

Slide 1: Management Presentation April 2021
Management Presentation April 2021

Slide 2: Free Writing Prospectus Statement
Free Writing Prospectus Statement This presentation highlights basic information about us and the offering to which this presentation relates. Because it is a summary, it does not contain all of the information that you should consider before investing in our securities. Anebulo Pharmaceuticals, Inc

Slide 3: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements Certain statements in this presentation may constitute “forward-looking statements” within the meaning of the Private Litigation Securities Litigation Reform Act of 1995. Those statements include, but are not limited to, statements with respect to

Slide 4: The Offering
The Offering Issuer Anebulo Pharmaceuticals, Inc. Transaction Type Initial Public Offering of Common Stock Anticipated NASDAQ Symbol: ANEB Shares Offered: 3,000,000 (100% Primary) IPO Price Range: $6.00 - $8.00 Overallotment Option: 15% (100% Primary) 22NW, LP, an entity controlled by Aron R. Englis

Slide 5: Investment highlights
Investment highlights Addressing unmet medical need to treat cannabinoid overdose, a large and growing market • No product is approved for this indication and no other compound is further along in clinical testing • In 2018, ~1.7 million emergency department visits in U.S., growing 15% annually • Le

Slide 6: Leadership
Leadership Management Dan Schneeberger, MD, MBA Rex Merchant, CFA Linda Klumpers, PhD Chief Executive Officer Chief Financial officer Chief Scientific Officer McKinsey & Co., JFL Capital Management, JFL Capital Management, Clinical Pharmacologist, specialized in clinical ADAR1 Capital Management Wes

Slide 7: ANEB-001 for Cannabinoid Overdose
ANEB-001 for Cannabinoid Overdose 7

Slide 8: Cannabis-associated ED visits are frequent and rapidly growing
Cannabis-associated ED visits are frequent and rapidly growing Number of annual cannabis-associated emergency department visits in the United States, 2006-2018 Growth of cannabis- Outside of NEDS (estimated) 1,741,747 associated emergency 1,600,000 department visits has Captured in NEDS 1,400,000 +1

Slide 9: Significant unmet medical need
Significant unmet medical need “Have had several pediatric Company-sponsored survey of 27 U.S. emergency room physicians patients require intubation (November 2020) secondary to cannabis overdose and would make a large impact on their care.” On average, the physicians saw 10.5 patients with cannabis

Slide 10: Marijuana legalization is increasing
Marijuana legalization is increasing Legalized Medical and Decriminalized Medical Decriminalized Fully illegal Marijuana is legal for recreational use in 16 states and is legal for medical use in 35 states Since 2012, recreational marijuana has gone from legal in no states to legal in 16 states 4 st

Slide 11: Legalization drives ED visits
Legalization drives ED visits Cannabis-Attributable ED Visits Four-year study at University of Colorado Hospital Edible Inhalable • Marijuana-related ED visits tripled after Colorado became the first U.S. state to allow n= recreational sales • 2-3 patients per day presented with severe 750 vomiting,

Slide 12: Potency of edibles tends to be deceiving
Potency of edibles tends to be deceiving Manufactured as familiar products to consumers, including candy bars or gummy snacks • Consumers often approach cannabis edibles with the same serving size expectations as non-cannabis products • Cannabis candy bar may contain 4x or more times a safe dose of

Slide 13: Synthetic cannabinoids are a growing problem
Synthetic cannabinoids are a growing problem Synthetic cannabinoids (commonly These drugs have serious potential side referred to as “spice” or “K2”) are the effects including seizures, renal failure fastest-growing class of psychoactive and death, and were responsible for a drug worldwide. well-pub

Slide 14: A promising solution for treating cannabinoid overdose
A promising solution for treating cannabinoid overdose ANEB-001 • CB1 antagonist. Blocks the effect of THC at the CB1 receptor. Well understood pharmacology. • Oral bioavailability. ANEB-001 is administered as an oral treatment in the form of a pill, capsule or tablet. • Rapid absorption. We believe

Slide 15: Well understood pharmacology de-risks clinical development
Well understood pharmacology de-risks clinical development THC THC ANEB-001 is a competitive antagonist at the human CB1 CB1 Receptor receptor with an affinity of ANEB-001 Cell membrane Cell membrane CB1 Receptor 0.6nM Effects Effects Good bioavailability and brain penetration (brain:plasma Feeling

Slide 16: ANEB-001 is rapidly absorbed and reaches potentially therapeutic blood levels
ANEB-001 is rapidly absorbed and reaches potentially therapeutic blood levels within 30 minutes Single Ascending Dose PK • n=18, 6 subjects/dose, 4 at 150mg 1400 • ANEB-001 is: 1200 – Rapidly absorbed 1000 ANEB-001 ng/ml – Extensively protein bound 800 – No cytochrome inhibition 600 • No serious adv

Slide 17: Phase 2 proof-of-concept trial: design
Phase 2 proof-of-concept trial: design • n=100, 25 healthy volunteers (HV) will be randomized to each of 3 doses Cohort 1: of ANEB-001 or placebo 50mg • All HVs will receive 10mg THC orally + placebo or drug • Endpoints: – 1° inhibition of primary central nervous system effect of THC Cohort 2: 100mg

Slide 18: Development plan
Development plan H1 2022 Readout Life- Cycle management Proof-of-Concept Pivotal Program* New Drug Application 5+ years of market exclusivity • 100 healthy • Design to be • Exploration of • Method of use patents filed volunteers determined strategic options for • Upside if additional IP • THC + 3 do

Slide 19: Growth strategy
Growth strategy • Develop and commercialize ANEB-001 antagonist in the U.S. • Explore strategic collaborations to commercialize ANEB-001 • Ensure capital-efficient business model by outsourcing clinical research and data management • Introduce product candidate extensions - Non-oral formulation of A

Slide 20: Strategic Implementation
Strategic Implementation • Continued lean corporate structure with low burn rate (overhead ~$3M/year) • Phase 2 proof-of-concept trial to commence in Q4 2021 and results expected H1 2022 (Cost: ~$2M) • Continued strengthening of IP portfolio • Additional development of formulations/indications for A

Slide 21: In summary
In summary Addressing unmet medical need in large and growing market, with cannabinoid overdose becoming an increasingly widespread health issue ANEB-001 is a de-risked asset with well understood mechanism of action as a CB1 antagonist Rapid path to proof-of-concept with Phase 2 study commencing in

Slide 22: Appendix
Appendix 22

Slide 23: ED physicians are likely to prescribe a drug with our target product profile
ED physicians are likely to prescribe a drug with our target product profile and believe that it would reduce the need for supportive medication We sponsored a survey of 27 Emergency room physicians throughout the United States Assuming you have a cannabinoid antagonist available that will reverse c

Slide 24: Preclinical proof of concept: ANEB-001 reverses THC-induced hypolocomotion in mice
Preclinical proof of concept: ANEB-001 was able to reverse THC-induced hypolocomotion in mice Effect of ANEB-001 on THC-induced hypolocomotion 1000 P<0.01 800 P<0.01 TOTAL ACTIVE TIME (s) 600 400 200 0 veh/veh veh/THC ANEB-001/THC 30mg/kg po 30 min pre-test, total active time over 15 minutes in C57

Slide 25: Phase 1 Part B data in obese patients: weight loss
Phase 1 – Part B data in obese patients shows drug is on target: weight loss Change from Baseline (Day-1) in Body Weight for Individual Days for All Treatments (Efficacy Population) Placebo OD (D1-D14) 200 mg ANEB-001 (D1)/50mg OD ANEB-001 (D2-D14) 50 mg ANEB-001 (D1)/5mg OD ANEB-001 (D2-D14) 100 mg

Slide 26: Phase 1 Part B data in obese patients: reduced test meal energy intake
Phase 1 - Part B data in obese patients shows drug is on target: reduced test meal energy intake Test Meal Energy Intake D-1 D7 D14 2,500 2,000 Mean Energy Intake (kcal) 1,500 1,000 500 0 Placebo OD 50:5mg OD 75:15mg OD 200:50mg OD 100mg 26
Source: company website



